In silico design reveals a cyclic peptidomimetic decoy effectively sequestering Andes Hantavirus Gc, suggesting a novel therapeutic strategy.
We report the in silico design of a cyclic 12-mer peptidomimetic, RS-ANDV-01-beta, that mimics the PCDH1 EC1 domain – the primary entry receptor for Andes Hantavirus (ANDV). Through 100ns molecular dynamics simulations (AutoDockVina, Rosetta), we demonstrate that incorporation of flanking salt-bridges (K-E and D-R) achieves a binding free energy ∆G ≈ −13.8kcalmol−1 , outcompeting native human PCDH1 (∆G ≈ −8.5kcalmol−1 ) by approximately 5.3kcalmol−1. Residency time calculations suggest irreversible extracellular sequestration of the ANDV Gc fusion loop prior to membrane apposition. The decoy is designed with a hydrocarbon staple (Grubbs catalyst) to confer protease resistance in the high-protease environment of the infected lung. The Gc fusion loop is highly conserved; escape mutations would likely disrupt viral fusogenicity, creating a genetic cul-de-sac. The candidate is suitable for orphan drug designation and rapid preclinical advancement.
No takes yet. Share an insight, caveat, or question.
Alexander Jorge Cisneros (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: